{
  "docId": "019de076-91e2-76fd-b3d2-f30dde172711",
  "docSlug": "0239a71f9c69421092604a0a694fdb09",
  "documentTitle": "AstraZeneca | Investor Conference Presentation Deck | 26 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 16,
  "pageCount": 26,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "key_takeaways",
  "function": "size_opportunity",
  "density": "overcrowded",
  "nDataPoints": 5,
  "notes": "The slide uses a waterfall-style growth diagram for Ultomiris and a combination of bar charts and bulleted metrics for HPP assets.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de076-91e2-76fd-b3d2-f30dde172711/16",
  "deckHref": "/decks/019de076-91e2-76fd-b3d2-f30dde172711",
  "deckJsonHref": "/decks/019de076-91e2-76fd-b3d2-f30dde172711.json",
  "deckAnchorHref": "/decks/019de076-91e2-76fd-b3d2-f30dde172711#slide-16",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.6,
        "x": 0.03,
        "y": 0.84
      },
      "kind": "callout",
      "text": "Significant Ultomiris growth opportunities more than offset Soliris decline",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1abae4ab-4b56-4574-996e-fa1b8309dd8c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.2,
        "x": 0.67,
        "y": 0.45
      },
      "kind": "chart",
      "text": "Strensiq Total Revenue ($m)",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4ab99fd9-95b8-4f04-bb10-d02fe70dd715",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.6,
        "x": 0.03,
        "y": 0.25
      },
      "kind": "diagram",
      "text": "Ultomiris growth strategy diagram showing existing indications and new expansion areas",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e520831a-82d5-450f-b319-551410924796",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.15,
        "x": 0.8,
        "y": 0.73
      },
      "kind": "list",
      "text": "Phase III ongoing; Broader geographic reach; Label expansion",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "71d5e874-8649-4482-86de-e1015fb8d324",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.15,
        "x": 0.83,
        "y": 0.54
      },
      "kind": "metric",
      "text": "<50% diagnosed HPP patients are treated",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bc43911e-6430-4aaf-89dd-a051c6cdfc0f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.15,
        "x": 0.67,
        "y": 0.73
      },
      "kind": "metric",
      "text": "3x Strensiq addressable population",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ce04668f-0d6e-4b63-93a4-1b75069d1a53",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.85,
        "x": 0.03,
        "y": 0.15
      },
      "kind": "title",
      "text": "Expanded opportunities for Ultomiris and next-gen HPP supports sustained growth",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "926b6cb9-a88e-455f-a0fd-9febb1714c7f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.03,
        "y": 0.07
      },
      "kind": "title",
      "text": "Rare disease – durable commercial portfolio",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2b3254da-2048-462b-ab56-d46ff5de9641",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Waterfall chart",
      "slug": "waterfall-chart",
      "agent": null,
      "layer": "slide",
      "matchId": "afc5238e-558d-4814-a9db-96325034faf8",
      "evidence": "Ultomiris growth strategy diagram showing existing indications and new expansion areas",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "growth-strategy",
      "slug": null,
      "matchId": "c7f185d2-773d-4f47-af7b-a00a7ebb2cbd",
      "evidence": "Visual representation of growth drivers for existing and new indications",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 17,
      "from": 15,
      "beatId": "f8397b24-3413-4fd3-a720-393bac88f957",
      "arcName": "Rags to Riches",
      "arcSlug": "rags-to-riches",
      "beatName": "The Breakthrough",
      "beatSlug": "rags-to-riches-the-breakthrough",
      "evidence": "The deck highlights AstraZeneca's pipeline momentum and growth potential.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 17,
      "from": 15,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "328d8b39-68a9-4a4f-8944-dc6948d92940",
      "evidence": "The deck highlights the potential benefits of AstraZeneca's pipeline and growth strategy.",
      "position": 1,
      "objective": "The cost of not investing in AstraZeneca's pipeline and growth strategy",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}